IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. - Yosifov DY; Robrecht S; Giza A; Maity PC; Riecke A; Schneider C; Jebaraj BMC; Dheenadayalan RP; Jumaa H; Young M; Kumar M; Müller L; et al. (HemaSphere, 2026)